152880-16-5

Upstream product

• 4093-28-1 methyl 4-acetamido-2-hydroxybenzoate 
• 106-96-7 propargyl bromide 

Downstream Products

• 89481-87-8 methyl 4-(acetylamino)-5-chloro-2-(2-propynyloxy)benzoate 
• 1082204-02-1 C₁₃H₁₅NO₅ 
• 4093-28-1 methyl 4-acetamido-2-hydroxybenzoate 
• 202664-66-2 methyl 4-acetylamino-2-methylbenzofuran-7-carboxylate 
• 132976-75-1 methyl 5-acetylamino-6-chloro-2H-1-benzopyran-8-carboxylate 

Relevant academic research and scientific papers

Investigation of Synthetic Routes to a Key Benzopyran Intermediate of a 5HT4 Agonist

The supply route to GlaxoSmithKline's 5HT4 receptor agonist 1 centred on the construction of key benzopyran fragment 2. Our attempts to define the final manufacturing route for this component are described through a series of disconnections. The systematic approach undertaken towards the construction of the benzopyran skeleton focused on cycli- sation strategies from appropriate precursors and evaluation of the performance of the key steps.

Synthesis and structure-activity relationship of 3-substituted benzamide, benzo[b]furan-7-carboxamide, 2,3-dihydrobenzo[b]furan-7- carboxamide, and indole-5-carboxamide derivatives as selective serotonin 5- HT4 receptor agonists

The title compounds (6-9) were prepared and evaluated for serotonin 5- HT4 agonistic activity in in vitro tests. Introducing a propyl or allyl group at the 3-position of benzamide caused only a slight enhancement of agonistic activity. Construction of the benzo[b']furan skeleton and 2,3- dihydrobenzo[b]furan skeleton caused a significant enhancement of the activity. 4-Amino-N-[2-(1-azabicyclo[3.3.0]octan-5-yl)ethyl]-5-chloro-2- methylbenzo[b]furan-7-carboxamide (7b) hemifumarate was as potent as cisapride. 4-Amino-N-[2-(1-azabicyclo[3.3.0]octan-5-yl)ethyl]-5-chloro-2,3- dihydro-2-methylbenzo[b]furan-7-carboxamide (8a) hemifumarate, 4-amino-N-[2- (1-azabicyclo [3.3.0]octan-5-yl)ethyl]5-chloro-2,3-dihydro-2- ethylbenzo[b]furan-7-carboxamide (8c) hemifumarate, and 4-amino-N-]2-(1- azabicyclo[3.3.0]octan-5-yl]-5-chloro-2,3-dihydro-2,3-dimethylhenzo[b]furan- 7-carboxamide (8d) hemifumarate were more potent than cisapride. Furthermore, 8a hemifumarate was free from dopamine D1, D2, serotonin 5-HT1, 5-HT2 and muscarine M1, M2 receptor binding activity in the in vitro tests. On the other hand, construction of the indole skeleton caused a remarkable decrease in activity.